Frontiers
US$ 28.67
glp-1/gip dual agonist weight loss The Emerging Role of GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction Unveiling Tirzepatide's Therapeutic Spectrum: A
Description
Melanie Jay, who studies the treatment and prevention of obesity at NYU Langone Health
This analysis concludes that while GLP-1 agonists demonstrate significant promise, their ultimate impact depends on addressing cost, accessibility, and long-term sustainability concerns
[Google Scholar] 8
Aging (Albany NY) 13 , 1342113429 (2021)
Have you taken a GLP-1 drug
In the 2022 SURMOUNT-1 study published in NEJM, three doses of tirzepatide were compared with placebo (1:1:1:1) to determine effects on percent weight change over the course of 72 weeks
